SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Show simple item record

dc.contributor.author Wibmer, Constantinos Kurt
dc.contributor.author Ayres, Frances
dc.contributor.author Hermanus, Tandile
dc.contributor.author Madzivhandila, Mashudu
dc.contributor.author Kgagudi, Prudence
dc.contributor.author Oosthuysen, Brent
dc.contributor.author Lambson, Bronwen E.
dc.contributor.author De Oliveira, Tulio
dc.contributor.author Vermeulen, Marion
dc.contributor.author Van der Berg, Karin
dc.contributor.author Rossouw, Theresa M.
dc.contributor.author Boswell, Michael
dc.contributor.author Ueckermann, Veronica
dc.contributor.author Meiring, Susan
dc.contributor.author Von Gottberg, Anne
dc.contributor.author Cohen, Cheryl
dc.contributor.author Morris, Lynn
dc.contributor.author Bhiman, Jinal N.
dc.contributor.author Moore, Penny L.
dc.date.accessioned 2021-04-07T07:26:39Z
dc.date.issued 2021
dc.description Supplementary Information: Supplementary Figs. 1 and 2 en_ZA
dc.description.abstract SARS-CoV-2 501Y.V2 (B.1.351), a novel lineage of coronavirus causing COVID-19, contains substitutions in two immunodominant domains of the spike protein. Here, we show that pseudovirus expressing 501Y.V2 spike protein completely escapes three classes of therapeutically relevant antibodies. This pseudovirus also exhibits substantial to complete escape from neutralization, but not binding, by convalescent plasma. These data highlight the prospect of reinfection with antigenically distinct variants and foreshadows reduced efficacy of spike-based vaccines. en_ZA
dc.description.department Immunology en_ZA
dc.description.department Internal Medicine en_ZA
dc.description.embargo 2021-09-02
dc.description.librarian hj2021 en_ZA
dc.description.sponsorship The South African Medical Research Council, the Wellcome Trust, US Centers for Disease Control and Prevention and the ELMA South Africa Foundation. en_ZA
dc.description.uri http://www.nature.com/nm en_ZA
dc.identifier.citation Wibmer, C.K., Ayres, F., Hermanus, T. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature Medicine (2021). https://doi.org/10.1038/s41591-021-01285-x. NYP. en_ZA
dc.identifier.issn 1078-8956 (print)
dc.identifier.issn 1546-170X (online)
dc.identifier.other 10.1038/s41591-021-01285-x
dc.identifier.uri http://hdl.handle.net/2263/79329
dc.language.iso en en_ZA
dc.publisher Springer en_ZA
dc.rights © The Author(s), under exclusive licence to Springer Nature America, Inc. 2021 en_ZA
dc.subject Infectious diseases en_ZA
dc.subject COVID-19 pandemic en_ZA
dc.subject Coronavirus disease 2019 (COVID-19) en_ZA
dc.subject Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) en_ZA
dc.title SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma en_ZA
dc.type Postprint Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record